Cargando…

Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia

OBJECTIVES: To describe age-specific and type-specific carcinogenic human papillomavirus (HPV) prevalence prior to large-scale effect of HPV vaccines in Estonia and to analyse the risk factors associated with carcinogenic HPV. DESIGN: Cross-sectional study using self-administered questionnaire and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pärna, Kersti, Nygård, Mari, Tisler, Anna, Toompere, Karolin, Naaber, Paul, Ratnik, Kaspar, Ķīvīte Urtāne, Anda, Zodzika, Jana, Stankūnas, Mindaugas, Baltzer, Nicholas, Uusküla, Anneli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255022/
https://www.ncbi.nlm.nih.gov/pubmed/37263686
http://dx.doi.org/10.1136/bmjopen-2022-069558
_version_ 1785056774078857216
author Pärna, Kersti
Nygård, Mari
Tisler, Anna
Toompere, Karolin
Naaber, Paul
Ratnik, Kaspar
Ķīvīte Urtāne, Anda
Zodzika, Jana
Stankūnas, Mindaugas
Baltzer, Nicholas
Uusküla, Anneli
author_facet Pärna, Kersti
Nygård, Mari
Tisler, Anna
Toompere, Karolin
Naaber, Paul
Ratnik, Kaspar
Ķīvīte Urtāne, Anda
Zodzika, Jana
Stankūnas, Mindaugas
Baltzer, Nicholas
Uusküla, Anneli
author_sort Pärna, Kersti
collection PubMed
description OBJECTIVES: To describe age-specific and type-specific carcinogenic human papillomavirus (HPV) prevalence prior to large-scale effect of HPV vaccines in Estonia and to analyse the risk factors associated with carcinogenic HPV. DESIGN: Cross-sectional study using self-administered questionnaire and self-collected vaginal swabs for detection of HPV infection. SETTING: Estonian Biobank database. PARTICIPANTS: Stratified random sample of women aged 30–33, 57–60 and 67–70 years living in one of the three largest counties in Estonia. Of 3065 women approached, 1347 (43.9%) returned questionnaires and specimens for HPV DNA detection. OUTCOME MEASURES: HPV prevalence and fully adjusted ORs with 95% CIs for risk factors. RESULTS: HPV prevalence was highest among women aged 30–33 years (18.7%; 95% CI 15.8 to 21.9) followed by those aged 67–70 years (16.7%; 95% CI 12.4 to 22.0) and 57–60 years (10.2%; 95% CI 7.8 to 13.3). HPV16 and HPV56 were the most common among women aged 30–33 years (both 4.0%; 95% CI 2.7 to 5.9), and HPV68 was the most common among women aged 57–60 years (2.8%; 95% CI 1.5 to 4.7) and 67–70 years (6.4%; 95% CI 3.6 to 10.4). Vaccination with nonavalent vaccine would have halved the carcinogenic HPV prevalence among women aged 30–33 years. The odds of infection with carcinogenic HPV were higher among women with six or more sexual partners among younger (OR 2.99; 95% CI 1.54 to 5.81) and older (OR 3.80; 95% CI 1.25 to 11.55) women and lower (OR 0.35; 95% CI 0.17 to 0.72) among younger married women. CONCLUSIONS: This study demonstrated U-shaped age-specific genotype profile of carcinogenic HPV prevalence, indicating that public health providers should focus on developing exit strategies for the cervical cancer screening programme in Estonia with a possible extension of HPV testing beyond the current screening age of 65 years. Generalisability of the findings of this study may be affected by the low response rate.
format Online
Article
Text
id pubmed-10255022
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-102550222023-06-10 Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia Pärna, Kersti Nygård, Mari Tisler, Anna Toompere, Karolin Naaber, Paul Ratnik, Kaspar Ķīvīte Urtāne, Anda Zodzika, Jana Stankūnas, Mindaugas Baltzer, Nicholas Uusküla, Anneli BMJ Open Epidemiology OBJECTIVES: To describe age-specific and type-specific carcinogenic human papillomavirus (HPV) prevalence prior to large-scale effect of HPV vaccines in Estonia and to analyse the risk factors associated with carcinogenic HPV. DESIGN: Cross-sectional study using self-administered questionnaire and self-collected vaginal swabs for detection of HPV infection. SETTING: Estonian Biobank database. PARTICIPANTS: Stratified random sample of women aged 30–33, 57–60 and 67–70 years living in one of the three largest counties in Estonia. Of 3065 women approached, 1347 (43.9%) returned questionnaires and specimens for HPV DNA detection. OUTCOME MEASURES: HPV prevalence and fully adjusted ORs with 95% CIs for risk factors. RESULTS: HPV prevalence was highest among women aged 30–33 years (18.7%; 95% CI 15.8 to 21.9) followed by those aged 67–70 years (16.7%; 95% CI 12.4 to 22.0) and 57–60 years (10.2%; 95% CI 7.8 to 13.3). HPV16 and HPV56 were the most common among women aged 30–33 years (both 4.0%; 95% CI 2.7 to 5.9), and HPV68 was the most common among women aged 57–60 years (2.8%; 95% CI 1.5 to 4.7) and 67–70 years (6.4%; 95% CI 3.6 to 10.4). Vaccination with nonavalent vaccine would have halved the carcinogenic HPV prevalence among women aged 30–33 years. The odds of infection with carcinogenic HPV were higher among women with six or more sexual partners among younger (OR 2.99; 95% CI 1.54 to 5.81) and older (OR 3.80; 95% CI 1.25 to 11.55) women and lower (OR 0.35; 95% CI 0.17 to 0.72) among younger married women. CONCLUSIONS: This study demonstrated U-shaped age-specific genotype profile of carcinogenic HPV prevalence, indicating that public health providers should focus on developing exit strategies for the cervical cancer screening programme in Estonia with a possible extension of HPV testing beyond the current screening age of 65 years. Generalisability of the findings of this study may be affected by the low response rate. BMJ Publishing Group 2023-06-01 /pmc/articles/PMC10255022/ /pubmed/37263686 http://dx.doi.org/10.1136/bmjopen-2022-069558 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology
Pärna, Kersti
Nygård, Mari
Tisler, Anna
Toompere, Karolin
Naaber, Paul
Ratnik, Kaspar
Ķīvīte Urtāne, Anda
Zodzika, Jana
Stankūnas, Mindaugas
Baltzer, Nicholas
Uusküla, Anneli
Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia
title Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia
title_full Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia
title_fullStr Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia
title_full_unstemmed Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia
title_short Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia
title_sort age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in estonia
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255022/
https://www.ncbi.nlm.nih.gov/pubmed/37263686
http://dx.doi.org/10.1136/bmjopen-2022-069558
work_keys_str_mv AT parnakersti agespecificandgenotypespecificcarcinogenichumanpapillomavirusprevalenceinacountrywithahighcervicalcancerburdenresultsofacrosssectionalstudyinestonia
AT nygardmari agespecificandgenotypespecificcarcinogenichumanpapillomavirusprevalenceinacountrywithahighcervicalcancerburdenresultsofacrosssectionalstudyinestonia
AT tisleranna agespecificandgenotypespecificcarcinogenichumanpapillomavirusprevalenceinacountrywithahighcervicalcancerburdenresultsofacrosssectionalstudyinestonia
AT toomperekarolin agespecificandgenotypespecificcarcinogenichumanpapillomavirusprevalenceinacountrywithahighcervicalcancerburdenresultsofacrosssectionalstudyinestonia
AT naaberpaul agespecificandgenotypespecificcarcinogenichumanpapillomavirusprevalenceinacountrywithahighcervicalcancerburdenresultsofacrosssectionalstudyinestonia
AT ratnikkaspar agespecificandgenotypespecificcarcinogenichumanpapillomavirusprevalenceinacountrywithahighcervicalcancerburdenresultsofacrosssectionalstudyinestonia
AT kiviteurtaneanda agespecificandgenotypespecificcarcinogenichumanpapillomavirusprevalenceinacountrywithahighcervicalcancerburdenresultsofacrosssectionalstudyinestonia
AT zodzikajana agespecificandgenotypespecificcarcinogenichumanpapillomavirusprevalenceinacountrywithahighcervicalcancerburdenresultsofacrosssectionalstudyinestonia
AT stankunasmindaugas agespecificandgenotypespecificcarcinogenichumanpapillomavirusprevalenceinacountrywithahighcervicalcancerburdenresultsofacrosssectionalstudyinestonia
AT baltzernicholas agespecificandgenotypespecificcarcinogenichumanpapillomavirusprevalenceinacountrywithahighcervicalcancerburdenresultsofacrosssectionalstudyinestonia
AT uuskulaanneli agespecificandgenotypespecificcarcinogenichumanpapillomavirusprevalenceinacountrywithahighcervicalcancerburdenresultsofacrosssectionalstudyinestonia